Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The companies clash over survival curve similarities – and differences.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
After ZW171's exit, ZW251 enters the clinic.
Petosemtamab's phase 2 data in this setting should come by the year end.
The company is to test its KLK2-targeting pasritamig in a late-line setting.
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
